Episode
A Psychedelic and Cannabis Research Revolution On the Horizon?
- Podcast
- Blunt Business
- Published
- Apr 22, 2026
- Duration seconds
- 1768
- Processing state
not_requested- Canonical source
- https://cannabisradio.com/audio/7919
Actions
POST https://stenobird.com/v1/public/podcasts/blunt-business-326858/episodes/a-psychedelic-and-cannabis-research-revolution-on-the-horizon/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/blunt-business-326858/a-psychedelic-and-cannabis-research-revolution-on-the-horizon.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
This episode of Blunt Business explores a significant shift in federal drug policy following a new executive order aimed at accelerating research into psychedelics like LSD, psilocybin, and ibogaine for treating mental health disorders. The newly signed executive order to direct the FDA to fast-track these compounds through new "National Priority" vouchers. Beyond psychedelics, the host discusses the impact of GLP-1 weight-loss drugs (like Ozempic) on the cannabis market, noting that dispensaries are seeing a shift in consumer preference toward lower-dose products to mitigate "the munchies." Advertising Inquiries: https://redcircle.com/brands Privacy & Opt-Out: https://redcircle.com/privacy